• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2.多电极射频消融治疗直径大于3cm且巴塞罗那临床肝癌分期为A至B2期的肝细胞癌患者的疗效
Liver Cancer. 2016 Feb;5(1):8-20. doi: 10.1159/000367755. Epub 2015 Dec 15.
2
Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma.切换单极射频消融可改善中等大小肝癌的长期疗效。
Eur Radiol. 2021 Nov;31(11):8649-8661. doi: 10.1007/s00330-021-07729-9. Epub 2021 Apr 25.
3
Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.经导管动脉化疗栓塞联合或不联合射频消融治疗巴塞罗那临床肝癌分期 B 期肝细胞癌的疗效比较。
AJR Am J Roentgenol. 2018 Apr;210(4):891-898. doi: 10.2214/AJR.17.18177. Epub 2018 Feb 7.
4
Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study.射频消融与手术切除治疗早期肝细胞癌:一项澳大利亚多中心研究
Scand J Gastroenterol. 2015 May;50(5):567-76. doi: 10.3109/00365521.2014.953572. Epub 2015 Jan 23.
5
Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.经导管动脉化疗栓塞联合射频消融治疗巴塞罗那临床肝癌分期 A 或 B 期肝细胞癌患者的临床结局改善,无论肿瘤大小:单中心回顾性病例对照研究结果。
BMC Cancer. 2019 Oct 22;19(1):983. doi: 10.1186/s12885-019-6237-5.
6
[Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma].[射频消融治疗晚期肝细胞癌的疗效]
Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):256-60. doi: 10.3760/cma.j.issn.1007-3418.2012.04.006.
7
Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.射频消融联合经动脉化疗栓塞治疗巴塞罗那临床肝癌分期A期不可治愈性肝细胞癌患者的疗效与安全性
Korean J Gastroenterol. 2019 Mar 25;73(3):167-176. doi: 10.4166/kjg.2019.73.3.167.
8
Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.射频消融与手术治疗血管周围型肝细胞癌:长期疗效的倾向评分分析。
J Hepatol. 2018 Jul;69(1):70-78. doi: 10.1016/j.jhep.2018.02.026. Epub 2018 Mar 8.
9
[Long term (5 years) outcome of radiofrequency ablation for hepatocellular carcinoma in 256 cases].256例肝细胞癌患者射频消融的长期(5年)疗效
Beijing Da Xue Xue Bao Yi Xue Ban. 2005 Dec 18;37(6):671-2.
10
Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma.射频消融在中期肝细胞癌治疗中的应用。
J Gastroenterol Hepatol. 2017 Mar;32(3):695-700. doi: 10.1111/jgh.13586.

引用本文的文献

1
Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma.经动脉化疗栓塞术(D-TACE)联合射频消融术(D-RFA)治疗不可切除性大肝细胞癌的疗效与安全性
Front Oncol. 2025 Jul 28;15:1530951. doi: 10.3389/fonc.2025.1530951. eCollection 2025.
2
miR-101-3p-mediated role of PDZK1 in hepatocellular carcinoma progression and the underlying PI3K/Akt signaling mechanism.miR-101-3p介导的PDZK1在肝细胞癌进展中的作用及潜在的PI3K/Akt信号机制。
Cell Div. 2024 Mar 26;19(1):9. doi: 10.1186/s13008-023-00106-6.
3
Efficacy and Safety of Microwave Ablation Assisted by Ultrasound Fusion Imaging for Primary and Secondary Liver Cancers with a Diameter of 3-7 Cm.超声融合成像辅助微波消融治疗直径3 - 7厘米原发性和继发性肝癌的疗效与安全性
J Hepatocell Carcinoma. 2023 Oct 18;10:1839-1848. doi: 10.2147/JHC.S424009. eCollection 2023.
4
Long-term outcome and eligibility of radiofrequency ablation for hepatocellular carcinoma over 3.0 cm in diameter.直径超过 3.0 厘米的肝细胞癌射频消融治疗的长期疗效和适应证。
Sci Rep. 2023 Sep 28;13(1):16286. doi: 10.1038/s41598-023-43516-w.
5
Stereotactic Microwave Ablation of Hepatocellular Carcinoma: The Impact of Tumor Size and Minimal Ablative Margin on Therapeutic Success.立体定向微波消融治疗肝细胞癌:肿瘤大小和最小消融边界对治疗效果的影响。
Tomography. 2022 Dec 26;9(1):50-59. doi: 10.3390/tomography9010005.
6
Multipolar radiofrequency ablation via three bipolar electrodes with C-arm type X-ray fluoroscopy assistance for hepatocellular carcinoma: An observational study.经 C 臂型 X 射线透视辅助的三极双极电极多极射频消融治疗肝细胞癌:一项观察性研究。
Medicine (Baltimore). 2022 Sep 23;101(38):e30725. doi: 10.1097/MD.0000000000030725.
7
NIR-II emissive AIEgen photosensitizers enable ultrasensitive imaging-guided surgery and phototherapy to fully inhibit orthotopic hepatic tumors.近红外二区发光的聚集诱导发光型光敏剂能够实现超灵敏的成像引导手术和光疗,从而完全抑制原位肝肿瘤。
J Nanobiotechnology. 2021 Dec 13;19(1):419. doi: 10.1186/s12951-021-01168-w.
8
Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status.肝细胞癌的图像引导局部非血管介入治疗:现状
J Interv Med. 2020 Oct 12;4(1):1-7. doi: 10.1016/j.jimed.2020.10.008. eCollection 2021 Feb.
9
The Incidence of Bacteremia and Risk Factors of Post-Radiofrequency Ablation Fever for Patients with Hepato-Cellular Carcinoma.肝细胞癌患者菌血症的发生率及射频消融术后发热的危险因素
Cancers (Basel). 2021 Oct 22;13(21):5303. doi: 10.3390/cancers13215303.
10
Initial Incomplete Thermal Ablation Is Associated With a High Risk of Tumor Progression in Patients With Hepatocellular Carcinoma.初次不完全热消融与肝细胞癌患者肿瘤进展的高风险相关。
Front Oncol. 2021 Oct 18;11:760173. doi: 10.3389/fonc.2021.760173. eCollection 2021.

本文引用的文献

1
Surgical and Locoregional Therapy of HCC: TACE.肝癌的手术及局部区域治疗:经动脉化疗栓塞术
Liver Cancer. 2015 Sep;4(3):165-75. doi: 10.1159/000367739. Epub 2015 Jul 10.
2
Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.肝细胞癌肿瘤消融的最新进展
Liver Cancer. 2015 Sep;4(3):176-87. doi: 10.1159/000367740. Epub 2015 Jul 17.
3
Thrombocytopenia as an inexpensive, valuable predictor for survival in patients with hepatocellular carcinoma.血小板减少症作为肝细胞癌患者生存的一种廉价且有价值的预测指标。
Scand J Gastroenterol. 2014 Dec;49(12):1507-8. doi: 10.3109/00365521.2014.962076. Epub 2014 Oct 2.
4
Local ablation for hepatocellular carcinoma in taiwan.台湾地区肝细胞癌的局部消融治疗
Liver Cancer. 2013 Apr;2(2):73-83. doi: 10.1159/000343843.
5
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.中危(BCLC B)期肝细胞癌患者的异质性:提出一种亚分类以促进治疗决策。
Semin Liver Dis. 2012 Nov;32(4):348-59. doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8.
6
Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.射频消融联合或不联合经导管动脉化疗栓塞治疗肝细胞癌:一项前瞻性随机试验。
J Clin Oncol. 2013 Feb 1;31(4):426-32. doi: 10.1200/JCO.2012.42.9936. Epub 2012 Dec 26.
7
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南:肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
8
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of hepatocellular carcinoma.经皮射频消融使用内部冷却湿电极治疗肝细胞癌。
AJR Am J Roentgenol. 2012 Feb;198(2):471-6. doi: 10.2214/AJR.11.6583.
9
Percutaneous radiofrequency ablation with multiple electrodes for medium-sized hepatocellular carcinomas.经皮射频消融多电极治疗中等大小肝癌。
Korean J Radiol. 2012 Jan-Feb;13(1):34-43. doi: 10.3348/kjr.2012.13.1.34. Epub 2011 Dec 23.
10
Local-regional treatment of hepatocellular carcinoma.肝癌的局部区域治疗。
Radiology. 2012 Jan;262(1):43-58. doi: 10.1148/radiol.11110144.

多电极射频消融治疗直径大于3cm且巴塞罗那临床肝癌分期为A至B2期的肝细胞癌患者的疗效

The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2.

作者信息

Lin Chen-Chun, Cheng Ya-Ting, Chen M Wei-Ting, Lin Shi-Ming

机构信息

Division of Hepatology, Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Lin-Kuo, Chang Gung University, Taoyuan, Taiwan.

出版信息

Liver Cancer. 2016 Feb;5(1):8-20. doi: 10.1159/000367755. Epub 2015 Dec 15.

DOI:10.1159/000367755
PMID:26989656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4789949/
Abstract

Outcomes of hepatocellular carcinoma (HCC) lesions >3.0 cm in size including Barcelona Clinic Liver Cancer (BCLC) stage B after radiofrequency ablation (RFA) with a single electrode remain unsatisfactory. This study aimed to investigate the outcomes of RFA with multiple electrodes (ME-RFA) for HCC tumors 3.1-7.0 cm in size and BCLC stage B. This retrospective study included 70 consecutive patients with 58 medium- (3.1-5.0 cm) and 17 large- (5.1-7.0 cm) sized HCCs after ME-RFA using a controller. Outcomes in terms of complete response, primary technique effectiveness, local tumor progression, and overall survival were investigated. After 1-4 applications of ME-RFA, the rates of complete response and PTE in medium-sized tumors were 79.3% and 91.4%, respectively, and in large tumors were 76.5% and 94.1%, respectively. Overall, the major complication rate was 5.7%. After a median 21-month follow-up period, both two- and three-year estimated overall survival rates were above 80%. There were no significant differences in overall survival and local tumor progression rates between medium- and large-size tumors and among BCLC stages A, B1 and B2. A complete response to ME-RFA was the only significant factor associated with improved survival (p=0.008). In conclusion, ME-RFA can effectively treat 3.1-7.0-cm sized HCCs with a comparable outcome between medium- and large-size tumors and among BCLA stages A to B2.

摘要

对于大小>3.0 cm的肝细胞癌(HCC)病变,包括巴塞罗那临床肝癌(BCLC)分期为B期的病变,采用单电极射频消融(RFA)的治疗效果仍不尽人意。本研究旨在探讨多电极RFA(ME-RFA)治疗大小为3.1 - 7.0 cm且BCLC分期为B期的HCC肿瘤的疗效。这项回顾性研究纳入了70例连续患者,这些患者使用控制器接受ME-RFA治疗,其中有58个中等大小(3.1 - 5.0 cm)和17个大尺寸(5.1 - 7.0 cm)的HCC。研究了完全缓解、主要技术有效性、局部肿瘤进展和总生存率等方面的结果。在进行1 - 4次ME-RFA治疗后,中等大小肿瘤的完全缓解率和主要技术有效性分别为79.3%和91.4%,大尺寸肿瘤分别为76.5%和94.1%。总体而言,主要并发症发生率为5.7%。经过中位21个月的随访期,两年和三年的估计总生存率均高于80%。中等大小和大尺寸肿瘤之间以及BCLC分期A、B1和B2之间的总生存率和局部肿瘤进展率没有显著差异。对ME-RFA的完全缓解是与生存率提高相关的唯一显著因素(p = 0.008)。总之,ME-RFA可以有效治疗大小为3.1 - 7.0 cm的HCC,中等大小和大尺寸肿瘤之间以及BCLA分期A至B2之间的疗效相当。